Hovione & iBET Comes Together To Launch ViSync® For Next-Gen Cell Therapy

Hovione, renowned for its expertise in spray drying and particle engineering, and iBET, a pioneering biotech research institute, have officially launched ViSync® Technologies, a new joint venture in cell and gene therapy. The establishment of this company is based in the Lisbon region of Portugal, reflecting the enthusiasm for joint innovation and partnership between the parent companies. 

ViSync® focuses on providing innovative solutions to the unfulfilled technical needs of the pharmaceutical industry in the cell and gene therapy section. It will influence Hovione's core expertise in pharmaceutical development, particle engineering and the industrialisation of pharmaceutical technologies. This will also continue along with iBET's pioneering research in biotechnological sciences, to develop technologies that enhance the delivery and stabilization of modern therapies, that will be the prime concern of  ViSync®.

Jean-Luc Herbeaux, CEO of Hovione, stated “We are delighted to join forces with iBET - a leading R&D organization in Biotechnology and Life Sciences – in the establishment of ViSync®. By combining Hovione´s expertise in drug formulation, manufacturing process development and scale up with iBET´s broad understanding of new modalities, we aim to devise new solutions to help pharma companies launch innovative medicines and improve health outcomes for patients.”  

Paula Alves, CEO of iBET, said in a statement, “The creation of ViSync® marks a significant milestone for iBET. By combining our cutting-edge biotechnological research in the cell and gene therapy fields with Hovione’s extensive pharmaceutical development expertise, we are well-positioned to develop innovative approaches for targeted delivery and stabilization of new modality therapies. We are excited about the potential of ViSync® to drive substantial advancements and deliver significant benefits to patients worldwide.”